+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ranibizumab"

Ranibizumab Global Market Report 2024 - Product Thumbnail Image

Ranibizumab Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • February 2025
  • 273 Pages
  • Global
From
From
From
From
From
Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024 - Product Thumbnail Image

Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 240 Pages
  • Global
From
From
Central Retinal Vein Occlusion - Pipeline Insight, 2024 - Product Thumbnail Image

Central Retinal Vein Occlusion - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Thumbnail Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
Loading Indicator

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders. Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more